Skip to content
zameds
Loading the molecular structure
C9H14N5O4P287.21 g/mol

[(2R)-1-(6-Aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 464205.

Registration

Applicants
1
Registrations
1

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Cipla Medpro (Pty) LtdTrilef400mg, 300 mg, 300 mg560483.482Not determinedPIPIL

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Trilef

EACH TABLET CONTAINS EFAVIRENZ 400,0 mg LAMIVUDINE 300,0 mg TENOFOVIR DISOPROXIL EQUIVALENT TO TENOFOVIR DISOPROXIL 245,0 mg

400mg, 300 mg, 300 mgTablet560483.48256/20.2.8/0483.482Approved 2 May 2023RegisteredNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Dolutegravir

    Consolidated Schedules 06 July 2026, line 6100

  • S4: Efavirenz

    Consolidated Schedules 06 July 2026, line 6159

  • S4: Emtricitabine

    Consolidated Schedules 06 July 2026, line 6178

  • S4: Lamivudine

    Consolidated Schedules 06 July 2026, line 6850

  • S4: Tenofovir

    Consolidated Schedules 06 July 2026, line 8130

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading...
Loading Wikipedia summary

SAHPRA documents

These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.

Research articles

Loading...
Loading PubMed articles